文献速递炎症性肠病

口服利特昔替尼和布雷波替尼治疗中重度溃疡性结肠炎:一项随机2b期研究结果

Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-01-06

这项2b期平行组双盲伞式研究将319例中重度活动性溃疡性结肠炎患者随机分配接受8周诱导治疗:利特昔替尼20、70、200 mg,布雷波替尼10、30、60 mg或安慰剂每日一次。主要终点为第8周总Mayo评分。两种药物各剂量组诱导治疗均比安慰剂更有效,短期安全性可接受。

要点

  • 利特昔替尼200 mg组第8周总Mayo评分较安慰剂调整后平均降低4.6分(90%CI -5.8至-3.5)。
  • 布雷波替尼60 mg组第8周总Mayo评分较安慰剂调整后平均降低3.2分(90%CI -4.3至-2.1)。
  • 不良事件大多为轻度,无严重带状疱疹感染病例。

核心结论

  • 利特昔替尼和布雷波替尼诱导治疗对中重度活动性溃疡性结肠炎比安慰剂更有效,短期安全性可接受。

研究设计与样本

  • 2b期、平行组、双盲伞式研究,随机分配患者接受8周诱导治疗,每日一次口服利特昔替尼(20、70、200 mg)、布雷波替尼(10、30、60 mg)或安慰剂。
  • 319例患者被随机分配,317例接受了利特昔替尼(n=150)、布雷波替尼(n=142)或安慰剂(n=25)治疗。
  • 主要终点为第8周总Mayo评分(TMS)。

主要发现

  • 第8周安慰剂调整后平均TMS(90%CI):利特昔替尼20 mg为-2.0(-3.2至-0.9),P=.003;70 mg为-3.9(-5.0至-2.7),P<.001;200 mg为-4.6(-5.8至-3.5),P<.001。
  • 第8周安慰剂调整后平均TMS(90%CI):布雷波替尼10 mg为-1.8(-2.9至-0.7),P=.009;30 mg为-2.3(-3.4至-1.1),P=.001;60 mg为-3.2(-4.3至-2.1),P<.001。
  • 第8周安慰剂调整后改良临床缓解率估计值(90%CI):利特昔替尼20 mg为13.7%(0.5%-24.2%),70 mg为32.7%(20.2%-45.3%),200 mg为36.0%(23.6%-48.6%)。
  • 第8周安慰剂调整后改良临床缓解率估计值(90%CI):布雷波替尼10 mg为14.6%(1.9%-25.7%),30 mg为25.5%(11.0%-38.1%),60 mg为25.5%(11.0%-38.1%)。
  • 感染发生率:布雷波替尼组16.9%(12.5%-23.7%),利特昔替尼组8.7%(5.2%-13.4%),安慰剂组4.0%(0.2%-17.6%);发生1例心肌梗死死亡(利特昔替尼组)和1例血栓栓塞事件(布雷波替尼组),均被认为与研究药物无关。

关键数值与推荐

  • 主要终点为第8周总Mayo评分(TMS)。
  • 改良临床缓解率按第8周安慰剂调整后比例估计。
  • 不良事件大多为轻度,无严重带状疱疹感染病例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The efficacy and safety of ritlecitinib (oral JAK3/TEC family kinase inhibitor) and brepocitinib (oral TYK2/JAK1 inhibitor) as induction therapy were assessed in patients with active, moderate-to-severe ulcerative colitis. METHODS: This phase 2b, parallel-arm, double-blind umbrella study randomized patients with moderate-to-severe ulcerative colitis to receive 8-week induction therapy with ritlecitinib (20, 70, 200 mg), brepocitinib (10, 30, 60 mg), or placebo once daily. The primary endpoint was total Mayo Score (TMS) at week 8. RESULTS: Of 319 randomized patients, 317 received ritlecitinib (n = 150), brepocitinib (n = 142), or placebo (n = 25). The placebo-adjusted mean TMSs (90% confidence interval) at week 8 were -2.0 (-3.2 to -0.9), -3.9 (-5.0 to -2.7), and -4.6 (-5.8 to -3.5) for ritlecitinib 20, 70, and 200 mg, respectively (P = .003, P < .001, P < .001), and -1.8 (-2.9 to -0.7), -2.3 (-3.4 to -1.1), and -3.2 (-4.3 to -2.1) for brepocitinib 10, 30, and 60 mg, respectively (P = .009, P = .001, P < .001). Estimates (90% confidence interval) for placebo-adjusted proportions of patients with modified clinical remission at week 8 were 13.7% (0.5%-24.2%), 32.7% (20.2%-45.3%), and 36.0% (23.6%-48.6%) for ritlecitinib 20, 70, and 200 mg, respectively, and 14.6% (1.9%-25.7%), 25.5% (11.0%-38.1%), and 25.5% (11.0%-38.1%) for brepocitinib 10, 30, and 60 mg, respectively. Adverse events were mostly mild, and there were no serious cases of herpes zoster infection. Infections were observed with brepocitinib (16.9% [12.5%-23.7%]), ritlecitinib (8.7% [5.2%-13.4%]), and placebo (4.0% [0.2%-17.6%]). One death due to myocardial infarction (ritlecitinib) and 1 thromboembolic event (brepocitinib) occurred; both were considered unrelated to study drug. CONCLUSIONS: Ritlecitinib and brepocitinib induction therapies were more effective than placebo for the treatment of moderate-to-severe active ulcerative colitis, with an acceptable short-term safety profile. CLINICALTRIALS: gov number: NCT02958865.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Sandborn WJ, Danese S, Leszczyszyn J, et al. Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study. Clin Gastroenterol Hepatol. 2023. PMID: 36623678. doi:10.1016/j.cgh.2022.12.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。